Chi­na bans GSK from drug pro­cure­ment ac­tiv­i­ties through April 2024

Fol­low­ing an in­spec­tion of GSK’s CD­MO Poz­nan, Poland-based site that iden­ti­fied ques­tion­able prac­tices, Chi­na has de­cid­ed to ban the com­pa­ny from par­tic­i­pat­ing in its cen­tral­ized drug pro­cure­ment pro­gram through April 29, 2024, ac­cord­ing to an Eng­lish trans­la­tion of a re­cent gov­ern­ment post­ing.

The plant in ques­tion is a GSK con­tract man­u­fac­trur­er’s, which sup­plies the uri­nary re­ten­tion drug du­tas­teride, and Chi­na’s State Food and Drug Ad­min­is­tra­tion found the com­pa­ny did not con­duct batch-by-batch and full-item in­spec­tions of the prod­ucts ex­port­ed to Chi­na, as well as iden­ti­fied de­fi­cien­cies in the pre­ven­tion and con­trol of mi­cro­bial con­t­a­m­i­na­tion risks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER